Single Photon Emission Computed Tomography (SPECT) Market - Growth, Trends, and Forecast (2020 - 2025)

The market is segmented by Type of Radioisotope, Applications (Cardiology, Oncology, Neurology, Other), and Geography.

Market Snapshot

Study Period:

2016-2024

Base Year:

2019

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

Single-photon Emission Computed Tomography (SPECT) is used in the evaluation of disease processes based on functional and metabolic information of organs and cells.

The most widely used SPECT systems are based on the Anger gamma camera, usually involving dual detectors that rotate around the patient. The application of hybrid equipment and fused techniques has increasing importance in the field of imaging diagnostics. One of the most significant advantages of these methods is the simultaneous use of several modalities, which can give data about the morphological, functional, and molecular changes of the different diseases at the same time.

The integration of X-ray computed tomography (CT) into SPECT has recently emerged as an essential diagnostic tool in medical imaging, where anatomical details may delineate functional and metabolic information.

Furthermore, there is an increasing trend of dual-modality systems and organ-specific systems, to enhance the diagnostic capability of the equipment. In the past several years, there has been growing utilization of PET/CT, owing to the fact that functional and morphologic correlative images produced by this methodology improve diagnostic accuracy, and it is one of the factors that can impede the growth of the SPECT equipment market. Thus, owing to all factors mentioned above, the market is expected to witness satisfactory growth over the forecast period.

Scope of the Report

Single-photon emission computed tomography (SPECT) is a nuclear imaging technique that uses radioactive tracers and a scanner to record data, which a computer constructs into two or three-dimensional images. SPECT has reportedly been combined with CT and MRI to provide detailed anatomical and metabolic information. 

Report scope can be customized per your requirements. Click here.

Key Market Trends

Gallium-67 to Witness Highest CAGR

Gallium-67 radioisotope is used for diagnosing inflammation, both acute and chronic infection, and tumors, such as Hodgkin’s disease, lymphoma (except for lymphocytic), hepatoma, and bronchogenic carcinoma. Mostly, it is used as a bone imaging agent.

Until FDG-PET emerged in the market, gallium-67 was of a gold standard for tumor diagnosis and staging. G-67 is cyclotron produced, and its half-life is 78 hours. Gallium SPECT scan increased sensitivity and lesion detection from 48% to 89% in lymphoma, and from 50% to 80% in infection. Hybrid imaging using Ga-67 SPECT/CT enables the correct localization of lymphoma lesions. Ga-67 is a commonly used agent for the imaging of inflammation, because of its ability to accumulate non-specifically in inflamed areas as a metal-transferrin complex, followed by further binding to transferrin receptors. Some of the market players, which provide Gallium Citrate GA-67 are Lantheus Medical Imaging and Mallinckrodt Nuclear. According to the data published by the United States Geological Survey (USGS), in 2016, the leading sources of imported gallium metal in the United States was from China, the United Kingdom, Ukraine, and Germany. While, the high purity primary refined gallium was produced in China, Japan, Slovakia, the United Kingdom, and the United States.

Thus, owing to the rising prevalence of various bone disorders and benefits associated with Gallium-67, the market is expected to witness a high growth rate over the forecast period.

To understand key trends, Download Sample Report

North America to Dominate the Market

The SPECT market in the United States is growing propelled by the advancements in technology, including hybrid imaging, the introduction of new radiopharmaceuticals for diagnosis, and the development of molecular imaging.

Technetium 99m (TC-99m) is the most widely used imaging agent, due to its versatility. According to the US Department of Energy (DOE), this molecule is found to be used in approximately 80% of nuclear diagnostic imaging procedures, or about 40,000 medical procedures in the United States, every day.

Recently, in March 2018, Canadian Nuclear Laboratory (CNL), Chalk River, discontinued the function of the nuclear reactor that processes molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m). With the exit of this company from using Tc-99m, there are only six suppliers left in the global market which are from North America region only. Therefore, North America is gaining attraction in the global market for Tc-99m. Hence, it is expected that this region will be dominating the market studied.

To understand geography trends, Download Sample Report.

Competitive Landscape

The market for Single Photon Emission Computed Tomography (SPECT) is moderately consolidated and consists mostly of global players such as Koninklijke Philips NV, Siemens AG, GE Healthcare, etc. With the growing burden of chronic diseases across the globe and the rising significance of SPECT in various diseases, few companies are expected to enter the market studied.

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Demand for SPECT Analysis in Radiopharmaceuticals

      2. 4.2.2 Growing Geriatric Population

      3. 4.2.3 Improvements in SPECT Imaging Technology

    3. 4.3 Market Restraints

      1. 4.3.1 Shorter Half-Life of Radioisotopes

      2. 4.3.2 Stringent Regulatory Guidelines

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type of Radioisotopes

      1. 5.1.1 Tc-99m

      2. 5.1.2 Tl-201

      3. 5.1.3 Ga-66

      4. 5.1.4 I-123

      5. 5.1.5 Others

    2. 5.2 By Application

      1. 5.2.1 Oncology

      2. 5.2.2 Cardiology

      3. 5.2.3 Neurology

      4. 5.2.4 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 US

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 UK

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Global Medical Solutions

      2. 6.1.2 NTP Radioisotopes SOC Ltd

      3. 6.1.3 Cardinal Health Inc.

      4. 6.1.4 GE Healthcare

      5. 6.1.5 Spectrum Dynamics Medical

      6. 6.1.6 Digirad Corporation

      7. 6.1.7 Gamma Medica Inc.

      8. 6.1.8 Curium

      9. 6.1.9 Bracco Imaging

  7. *List Not Exhaustive
  8. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

** Subject to Availability

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

Related Reports